Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Ipilimumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Metastatic prostate cancer

• Asymptomatic or minimally symptomatic

• Progression during hormonal therapy

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

Exclusion Criteria:

• Liver, lung or brain metastases

• Prior immunotherapy or chemotherapy for metastatic prostate cancer

• Autoimmune disease

• HIV, Hepatitis B, or Hepatitis C infection